36 recruiting, 13 active not recruiting, 7 not yet recruiting, 4 completed. 35 Phase 2, 26 Phase 1, 6 Phase 3, 3 Not applicable, 1 Early Phase 1.
Follow Large B-cell Lymphoma: new trials by email Literature Review of Large B-cell Lymphoma trials Research Report on Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma Fludarabine, Cyclophosphamide, CD70.CAR NK Cells - Large B-cell Lymphoma, Hodgkin Lymphoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 100 | 2026-12-28 | 2026-07-15 |
| Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas Golcadomide, Pemetrexed, Rituximab - Large B-cell Lymphoma, Central Nervous System Lymphoma | Phase 1 | Not yet recruiting | Allison Winter | 18 | 2026-10-01 | 2026-08-21 |
| GLORY: Glofit-GemOx With Liso-Cel For Lymphoma Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin - Lymphoma, B-cell Lymphomas | Phase 2 | Recruiting | Massachusetts General Hospital | 56 | 2026-09-15 | 2026-10-22 |
| Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Large B-cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 40 | 2026-06-15 | 2026-06-30 |
| LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure LME-Guided Combination Therapy Regimen, Glofitamab Monotherapy - Large B-cell Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 60 | 2026-05-14 | 2026-05-22 |
| Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma Leukapheresis, Lymphodepleting Chemotherapy - Large B-cell Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2026-03-17 | 2026-06-30 |
| NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma NT-I7, CAR T-cell therapy - Large B-cell Lymphoma | Phase 1 | Recruiting | Washington University School of Medicine | 24 | 2026-03-12 | 2026-09-29 |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel - Large B-cell Lymphoma, Lymphoma, B-Cell | Phase 3 | Recruiting | Lyell Immunopharma, Inc. | 400 | 2026-01-12 | 2026-08-04 |
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse | Phase 2 | Recruiting | University of Miami | 26 | 2026-01-07 | 2026-10-15 |
| Glofitamab in Real Life Glofitamab - Large B-cell Lymphoma | Recruiting | The Lymphoma Academic Research Organisation | 250 | 2025-12-01 | 2026-06-03 | |
| AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL AZD0486, R-mini-CHOP - Large B-cell Lymphoma | Phase 3 | Recruiting | AstraZeneca | 420 | 2025-11-11 | 2026-10-09 |
| The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study Glofitamab, PD-1 Inhibitor, Lenalidomide - Large B-cell Lymphoma, TP53 | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 24 | 2025-09-01 | 2025-11-20 |
| A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T Tislelizumab, Zanubrutinib, Tislelizumab + Zanubrutinib - Large B-cell Lymphoma | Phase 2 | Recruiting | University Health Network, Toronto | 76 | 2025-06-04 | 2026-06-09 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies UB-VV400, Rapamycin - Large B-cell Lymphoma | Phase 1 | Recruiting | Nanjing IASO Biotechnology Co., Ltd. | 70 | 2025-04-11 | 2025-09-18 |
| Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym Tafasitamab, Lenalidomide - Large B-cell Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 28 | 2025-03-19 | 2026-04-03 |
| A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies Surovatamig, Prednisone (or equivalent), Rituximab - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 408 | 2025-01-30 | 2026-09-08 |
| BHB & CAR-T for Lymphomas R-1,3-Butanediol - Large B-cell Lymphoma | Not applicable | Recruiting | Abramson Cancer Center at Penn Medicine | 5 | 2025-01-07 | 2026-02-23 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| Emapalumab Prevention of CAR-T Cell Associated Toxicities Emapalumab, Cyclophosphamide, Fludarabine Phosphate - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 28 | 2024-09-18 | 2026-10-06 |
Showing 20 of 68. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (22) · Lymphoma, Non-Hodgkin (15) · Lymphoma, B-Cell (12) · Lymphoma, Follicular (12) · Lymphoma (11) · Lymphoma, Mantle-Cell (11) · Recurrence (9) · Dendritic Cell Sarcoma, Interdigitating (6) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, B-Cell, Marginal Zone (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Burkitt Lymphoma (4) · Waldenstrom Macroglobulinemia (3) · Leukemia (2) · Autoimmune Diseases (1)
Hemic and Lymphatic Diseases (43) · Lymphatic Diseases (43) · Neoplasms by Histologic Type (43) · Immune System Diseases (42) · Immunoproliferative Disorders (42) · Lymphoproliferative Disorders (42) · Neoplasms (42) · Lymphoma (30) · Lymphoma, Non-Hodgkin (23) · Lymphoma, B-Cell (20) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Disease Attributes (13) · Hematologic Diseases (11) · Leukemia, Lymphoid (9)
Cyclophosphamide (15) · fludarabine (9) · Rituximab (7) · axicabtagene ciloleucel (7) · glofitamab (7) · Prednisone (5) · obinutuzumab (5) · Doxorubicin (4) · fludarabine phosphate (4) · Immunotherapy, Adoptive (3) · Lenalidomide (3) · Vincristine (3) · polatuzumab vedotin (3) · relmacabtagene autoleucel (3) · Dexamethasone (2)
M.D. Anderson Cancer Center (5) · Memorial Sloan Kettering Cancer Center (3) · Ruijin Hospital (3) · Shanghai Ming Ju Biotechnology Co., Ltd. (3) · Abramson Cancer Center at Penn Medicine (2) · AstraZeneca (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Lyell Immunopharma, Inc. (2) · Pell Bio-Med Technology Co., Ltd. (2) · Stanford University (2) · Washington University School of Medicine (2) · Allison Winter (1) · Allogene Therapeutics (1) · CRISPR Therapeutics AG (1) · Cancer Research UK (1)
United States (37) · China (19) · Australia (9) · Germany (6) · Japan (6) · United Kingdom (6) · Canada (5) · France (5) · Poland (5) · South Korea (5) · Taiwan (5) · Denmark (4) · Italy (4) · Spain (4) · Turkey (Türkiye) (4)
Chen-Lung Lin, MD (2) · Huilai Zhang (2) · Paolo Strati, MD (2) · Allison M Winter, MD (1) · Aloysius Ho, MD (1) · Dai Chihara, MD (1) · Dai Chihara, MD, PHD (1) · David Russler-Germain, M.D., Ph.D. (1) · David Shook, MD (1) · Dehui Zou (1) · Dehui Zou, Dr. (1)
PMID 41894687, PMID 36532014, PMID 38631712, PMID 41980020
2023 (2), 2025 (1), R01CA286488 (1)